Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...
After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has ...
After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...
Madrigal Pharmaceuticals (NasdaqGS:MDGL) reports nearly US$1b in first full year Rezdiffra sales. The company launches Rezdiffra in Germany, its first market in Europe. Madrigal secures extended US ...
By reaching the brink of $1 billion in annual sales, the threshold for blockbuster drugs, Rezdiffra has given Madrigal its ...
Today, I'll provide an update on the Rezdiffra launch, where we ended our first full year on the market at nearly $1 billion in net sales and solidified Rezdiffra as the foundational therapy in MASH.
In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The ...
The FDA approved Rezdiffra to treat non-cirrhotic non-alcoholic steatohepatitis (NASH). Photo courtesy of U.S. Food and Drug Administration/Flickr Millions of Americans whose livers develop scar ...
The price of Rezdiffra can vary depending on insurance coverage and eligibility for manufacturer savings programs. To help lower the long-term expenses of Rezdiffra, consider obtaining a 90-day supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results